AAV-mediated CYP46A1 delivery is beneficial in Alzheimer's disease models: towards a clinical application

被引：0

作者：

Alves, S. ^{[1
]}

Michaelsen-Preusse, K. ^{[2
]}

Audrain, M. ^{[1
]}

Aron-Badin, R. ^{[3
]}

Lamaziere, A. ^{[4
]}

Fol, R. ^{[1
]}

Braudeau, J. ^{[1
]}

Despres, G. ^{[4
]}

Fouquet, F. ^{[1
]}

Pradier, L. ^{[5
]}

Delatour, B. ^{[6
]}

Korte, M. ^{[2
]}

Hantraye, P. ^{[3
]}

Aubourg, P. ^{[1
]}

Cartier, N. ^{[1
]}

机构：

[1] CEA, INSERM, U1169, MIRCen, Fontenay Aux Roses, France

[2] TU Braunschweig, Div Cellular Neurobiol, Inst Zool, Braunschweig, Germany

[3] CEA, DSV, I2BM, MIRCen, F-92265 Fontenay Aux Roses, France

[4] Sorbonne Univ, INSERM, ERL 1157, Pierre & Marie Curie Paris 6, Paris, France

[5] Sanofi, Neurodegenerat & Pain Unit, Chilly Mazarin, France

[6] CNRS, UMR 7225, INSERM, U1127,Inst Cerveau & Moelle Epiniere, Paris, France

来源：

HUMAN GENE THERAPY | 2016年 / 27卷 / 11期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

P005

引用

页码：A47 / A47

页数：1

共 50 条

[41] Second Generation AAV-Mediated Gene Therapy to Mitigate Risk for Alzheimer's Disease in APOE4/4Homozygotes
Montel, Rachel A.
Frenk, Esther
Crystal, Ronald G.
Stiles, Katie M.
MOLECULAR THERAPY, 2022, 30 (04) : 395 - 395
[42] Second Generation APOE2+APOE4- AAV-Mediated Gene Therapy for APOE Homozygotes at Risk for Alzheimer's Disease
Montel, Rachel
Frenk, Esther
Crystal, Ronald G.
Stiles, Katie M.
MOLECULAR THERAPY, 2021, 29 (04) : 167 - 168
[43] CYP46A1 intron-2T/C polymorphism and Alzheimer's disease: An updated meta-analysis of 16 studies including 3960 cases and 3828 controls
Li, Min
Wang, Wei
Li, Yanping
Wang, Lei
Shen, Xiaoping
Tang, Zhenyu
NEUROSCIENCE LETTERS, 2013, 549 : 18 - 23
[44] APOE promoter, ACE1 and CYP46 polymorphisms and β-amyloid in Alzheimer's disease
Chalmers, KA
Culpan, D
Kehoe, PG
Wilcock, GK
Hughes, A
Love, S
NEUROREPORT, 2004, 15 (01) : 95 - 98
[45] Improved Delivery in a New Clinical Trial of AAV2-BDNF Gene Therapy for Alzheimer's Disease
Castle, Michael J.
Nagahara, Alan H.
Baltanas, Fernando C.
Kovacs, Imre
Barba, David
Bankiewicz, Krystof S.
Tuszynski, Mark H.
MOLECULAR THERAPY, 2020, 28 (04) : 560 - 561
[46] Suppression of Neurological Deterioration in the APP1.PSEN1/APOE4 Murine Model of Alzheimer's Disease by AAV-Mediated Expression of APOE2 Christchurch
Gunaydin, Caner
Lephart, Hailey C.
Stiles, Katie M.
Hackett, Neil R.
Kaminsky, Stephen M.
Sondhi, Dolan
Crystal, Ronald G.
MOLECULAR THERAPY, 2023, 31 (04) : 402 - 403
[47] Interim data from a phase 1 clinical trial of AAV-NGF (CERE-110) gene delivery in Alzheimer's disease
Arvanitakis, Zoe
Tuszynski, Mark H.
Bakay, Roy
Arends, Danielle
Potkin, Steven
Bartus, Raymond
Bennett, David
NEUROLOGY, 2007, 68 (12) : A233 - A234
[48] A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease
Rafii, Michael S.
Baumann, Tiffany L.
Bakay, Roy A. E.
Ostrove, Jeffrey M.
Siffert, Joao
Fleisher, Adam S.
Herzog, Christopher D.
Barba, David
Pay, Mary
Salmon, David P.
Chu, Yaping
Kordower, Jeffrey H.
Bishop, Kathie
Keator, David
Potkin, Steven
Bartus, Raymond T.
ALZHEIMERS & DEMENTIA, 2014, 10 (05) : 571 - 581
[49] Repression of mHTT Expression in Huntington's Disease Mouse Models by AAV-Mediated Expression of Zinc-Finger Protein-Repressor Transgene
Choi, Vivian W.
Chiocco, Matt J.
Klatte, Deb
Renee-Graham, Anne
Felice, Brian
Galbreath, Elizabeth J.
Gaur, Tripti
Sun, Kefeng
McNally, Jim
Zeitler, Bryan
Zhang, H. Steve
Carey, Galen
MOLECULAR THERAPY, 2019, 27 (04) : 34 - 35
[50] AAV-MEDIATED DELIVERY OF SUPPLEMENTAL TRNA RESCUES NEUROPATHY IN AMINOACYL-TRNA SYNTHETASE-ASSOCIATED MOUSE MODELS OF CHARCOT-MARIE-TOOTH DISEASE
Tadenev, Abigail
Harper, Scott
Burgess, Robert
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S164 - S164

← 1 2 3 4 5 →